CTOs on the Move

Lacerta Therapeutics

www.lacertatherapeutics.com

 
Clinical stage gene therapy company using a constellation of proprietary AAV vector technologies to develop novel treatments for central nervous system and lysosomal storage diseases
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Lacerta Therapeutics raised $30M on 08/09/2018

Similar Companies

Accelerator Life Science Partners

Accelerator Life Science Partners catalyzes the development and commercialization of breakthrough biotechnology innovations.

BIOMERIX

BIOMERIX is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AxxiTrials

AxxiTrials is a Irvington, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Freenome

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent cancer. We have pioneered the most comprehensive multiomics platform for early cancer detection through a routine blood draw. By combining deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, we are developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Our recent $270 Million Series C brings our financing to over $500 million from investors, including; Bain Capital, Perceptive Advisors, RA Capital, Polaris Partners, Andreessen Horowitz, funds and accounts advised by T. Rowe Price Associates, Inc., GV (formerly Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society`s BrightEdge Ventures, Data Collective Venture Capital, Novartis and Verily Life Sciences.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.